Capital SCF Advises on US$25 million investment in BioScale Inc.

Capital SCF, announced the completion of a US $25 million investment in BioScale Inc, led by Morningside Group. BioScale, based in Boston, is a privately-held life science company that develops, manufactures and promotes a new generation of protein analytics technology. Capital SCF, which focuses on the healthcare and technology sectors, acted as a financial advisor to BioScale.

Denise Valentine, partner at Capital SCF, said: “We were pleased to have the opportunity to work with BioScale as we quickly recognized the strength and differentiation of their offering. We believed that Morningside would be an ideal partner for BioScale. This deal demonstrates the Capital SCF team’s long-standing track record in global advisory work in the healthcare and technology sector”.

BioScale is a life science company that develops, manufactures and promotes a new generation of protein analytics technology to accelerate drug discovery, development and production of biological and pharmaceutical products. BioScale’s innovative ViBE systems enable ultra-sensitive detection and quantitation of proteins in complex samples used in research, clinical, bioprocessing, patient point-of-care and personalized medicine applications. Founded in 2002, the Company is headquartered in Cambridge, MA.